Related Experiment Videos
Hematopoietic stem-cell transplantation in globoid-cell leukodystrophy
W Krivit1, E G Shapiro, C Peters
1Department of Pediatrics, University of Minnesota School of Medicine, Minneapolis, USA.
The New England Journal of Medicine
|April 17, 1998
Summary
Allogeneic hematopoietic stem-cell transplantation restored enzyme levels and reversed central nervous system damage in globoid-cell leukodystrophy patients. This treatment offers a potential cure for this rare genetic disorder.
Area of Science:
- Neurology
- Genetics
- Hematology
Background:
- Globoid-cell leukodystrophy (GCL) is a severe genetic disorder caused by galactocerebrosidase deficiency, leading to progressive neurological decline.
- The deficiency results in the accumulation of toxic substances in the central nervous system (CNS), causing irreversible damage.
Purpose of the Study:
- To evaluate the efficacy of allogeneic hematopoietic stem-cell transplantation (HSCT) in GCL treatment.
- To determine if HSCT can provide a functional source of galactocerebrosidase and halt CNS deterioration.
Main Methods:
- Five children with GCL underwent allogeneic HSCT.
- Comprehensive assessments including enzyme levels, neurological exams, neuroimaging, and cerebrospinal fluid analysis were performed pre- and post-transplant.
Main Results:
- Successful engraftment of donor cells led to normalized leukocyte galactocerebrosidase levels in all patients.
- CNS deterioration was reversed in late-onset GCL cases, and symptoms were prevented in the infantile case.
- Neuroimaging and cerebrospinal fluid markers showed significant improvement, indicating CNS repair.
Conclusions:
- Allogeneic HSCT is a viable therapeutic strategy for GCL.
- The procedure can reverse established CNS damage and prevent further neurological decline in GCL patients.